Illumina - ILMN Stock Forecast, Price & News

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Canaccord Genuity Group decreased their price objective on shares of Illumina from $555.00 to $520.00 and set a "buy" rating for the company in a report on Friday, May 6th. Piper Sandler decreased their price objective on shares of Illumina from $460.00 to $360.00 and set a "na" rating for the company in a report on Sunday, May 15th. Cowen reduced their target price on shares of Illumina from $506.00 to $492.00 in a report on Friday, May 6th. Cowen set a $412.00 target price on shares of Illumina in a report on Tuesday, July 19th. Finally, Citigroup reduced their target price on shares of Illumina from $325.00 to $220.00 and set a "neutral" rating for the company in a report on Friday, July 8th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $384.45.

Illumina Stock Performance

Shares of NASDAQ:ILMN opened at $227.30 on Thursday. The firm has a fifty day moving average price of $203.00 and a 200-day moving average price of $276.39. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.85 and a quick ratio of 1.54. The stock has a market cap of $35.71 billion, a PE ratio of 49.41, a price-to-earnings-growth ratio of 1.75 and a beta of 1.15. Illumina has a 1 year low of $173.45 and a 1 year high of $526.00.

Insider Transactions at Illumina

In other news, SVP Susan H. Tousi sold 250 shares of the stock in a transaction on Friday, June 10th. The shares were sold at an average price of $214.85, for a total value of $53,712.50. Following the completion of the sale, the senior vice president now directly owns 41,833 shares of the company's stock, valued at $8,987,820.05. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, SVP Alexander Aravanis sold 539 shares of the company's stock in a transaction on Thursday, July 7th. The shares were sold at an average price of $200.00, for a total transaction of $107,800.00. Following the completion of the transaction, the senior vice president now owns 3,346 shares in the company, valued at $669,200. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Susan H. Tousi sold 250 shares of the company's stock in a transaction on Friday, June 10th. The stock was sold at an average price of $214.85, for a total transaction of $53,712.50. Following the transaction, the senior vice president now owns 41,833 shares of the company's stock, valued at approximately $8,987,820.05. The disclosure for this sale can be found here. Corporate insiders own 0.13% of the company's stock.